Testing a new antibiotic for drug-resistant pneumonia in the hospital
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 82 years old.
- You have pneumonia that started in the hospital or while on a breathing machine.
- Your pneumonia is caused by a type of bacteria that is resistant to many common antibiotics.
- You have not received more than 48 hours of antibiotics that would work against this bacteria before starting the study drug, or you are getting worse on your current treatment.
- You do not have serious kidney, liver, or heart problems, or certain other severe health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This study tests a new antibiotic called YK-1169 against a standard treatment for pneumonia that develops during a hospital stay or while on a breathing machine. It aims to see if the new drug works just as well or better.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.